Prevalence of human papillomavirus DNA and p16 in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis.

BACKGROUND

Although previous meta-analyses have examined human papillomavirus (HPV) DNA prevalence in penile cancer, none, to our knowledge, have assessed pooled HPV DNA prevalence in penile intraepithelial neoplasia or p16 percent positivity in penile cancer and penile intraepithelial neoplasia. Therefore, we aimed to examine the prevalence of HPV DNA and p16 positivity in penile cancer and penile intraepithelial neoplasia worldwide.

METHODS

In this systematic review and meta-analysis, we searched PubMed, Embase, and the Cochrane Library until July 24, 2017, for English-language articles published from Jan 1, 1986, onwards reporting the prevalence of HPV DNA and p16 positivity, either alone or in combination, in at least five cases of penile cancer or penile intraepithelial neoplasia. Only studies that used PCR or hybrid capture for the detection of HPV DNA and immunohistochemical staining or methylation for the detection of p16 were included. Data were extracted and subsequently crosschecked, and inconsistencies were discussed to reach consensus. Using random-effects models, we estimated the pooled prevalence and 95% CI of HPV DNA and p16 positivity in penile cancer and penile intraepithelial neoplasia, stratifying by histological subtype and HPV DNA or p16 detection method. Type-specific prevalence of HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, and HPV45 in penile cancer was estimated.

FINDINGS

Our searches identified 1836 non-duplicate records, of which 73 relevant papers (71 studies) were found to be eligible. The pooled HPV DNA prevalence in penile cancer (52 studies; n=4199) was 50·8% (95% CI 44·8-56·7; I=92·6%, p<0·0001). A high pooled HPV DNA prevalence was seen in basaloid squamous cell carcinomas (84·0%, 95% CI 71·0-93·6; I=48·0%, p=0·0197) and in warty-basaloid carcinoma (75·7%, 70·1-81·0; I=0%, p=0·52). The predominant oncogenic HPV type in penile cancer was HPV16 (68·3%, 95% CI 58·9-77·1), followed by HPV6 (8·1%, 4·0-13·7) and HPV18 (6·9%, 2·9-12·4). The pooled HPV DNA prevalence in penile intraepithelial neoplasia (19 studies; n=445) was 79·8% (95% CI 69·3-88·6; I=83·2%, p<0·0001). The pooled p16 percent positivity in penile cancer (24 studies; n=2295) was 41·6% (95% CI 36·2-47·0; I=80·6%, p<0·0001), with a high pooled p16 percent positivity in HPV-related squamous cell carcinoma (85·8%, 95% CI 72·1-95·4; I=56·4%, p=0·0011) as compared with non-HPV-related squamous cell carcinoma (17·1%, 7·9-29·1; I=78·3%, p<0·0001). Moreover, among HPV-positive cases of penile cancer, the p16 percent positivity was 79·6% (95% CI 65·7-90·7; I=89·9%, p<0·0001), compared with 18·5% (9·6-29·6; I=89·3%, p<0·0001) in HPV-negative penile cancers. The pooled p16 percent positivity in penile intraepithelial neoplasia (six studies; n=167) was 49·5% (95% CI 18·6-80·7).

INTERPRETATION

A large proportion of penile cancers and penile intraepithelial neoplasias are associated with infection with HPV DNA (predominantly HPV16), emphasising the possible benefits of HPV vaccination in men and boys.

FUNDING

None.